Search

everythinglearnresearchcommunity

for

Search:↓

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Low-dose oral minoxidil improved hair growth when topical treatments failed.

The document concludes that understanding and managing hair loss in cancer patients is important, and more research is needed for better treatments.

Certain drugs can worsen hair loss in people prone to androgenetic alopecia.

Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.

New cancer treatments are more precise and less toxic, improving survival rates, but Asia faces challenges in adopting these advancements.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Secondary aesthetic surgeries for gender reassignment are generally satisfying and advance overall aesthetic surgery techniques, but psychological support is important.

Two teenage boys lost hair after taking a drug for growth, which was not a known side effect for kids.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Current treatments for hair loss from chemotherapy are limited, but new methods are being researched.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.

Postmenopausal hyperandrogenism, a condition with symptoms like increased hair growth and acne, is usually caused by PCOS but can also be due to other factors. It's diagnosed by checking testosterone levels and treated either by removing the adrenal tumor or through antiandrogen therapy.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

The book concludes that despite progress, cancer drug treatments have not met the expectations set in the 1960s and 1970s.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Sex hormones like estrogen and testosterone may affect COVID-19 severity differently in men and women, potentially influencing prevention and treatment strategies.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.

Electric pulse treatments for breast cancer show promise in being safer and more effective, with fewer side effects.

Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.